Wednesday, September 01, 2021

Back to a semblance of normality: A couple of conversations

Hi all.

Life is back to a semblance of normality now. I've de-spammed/approved the comments on older posts and will try to read all of the comments as soon as practical.

As a brief update, Brian Sanders and I had a chat which is now up on the Peak Human website. It was fun. Nothing too detailed in the way of biochemistry and lots and lots of "I don't know about....." or "I don't have a framework to integrated that into..." sort of statements.

As life should be.

Peter from Hyperlipid on Are medical professionals giving the absolutely wrong advice?

The other thing which happened just before our vacation was a chat with Amber O'Hearn. She is really interested in sleep and diet, as in

The therapeutic properties of ketogenic diets, slow-wave sleep, and circadian synchrony

and it was a great privilege to throw in some ROS derived ideas which might have been helpful towards her presentation at AHS21

Does dietary mismatch affect us via sleep?

Very interesting. I have previously been sent a paper by a reader (long time ago) where death from sleep deprivation is an ROS phenomenon, largely centred on ROS damage to the gut. But, while fascinated, it didn't make a lot of sense to me until Amber filled in a lot of gaps. It still doesn't completely make sense but time and some thought might help with that!

I have to say, adenosine looks to be a very interesting molecule too, even if not directly ROS controlled...



Stefan said...

Welcome back. I hope you had a good holiday.
I enjoyed the conversion with Brian, thank you for doing that.

cavenewt said...

On a tangential topic, via Mike Eades' always thought-provoking newsletter The Arrow.

'“Ground-breaking” cholesterol jab'“ground-breaking”-cholesterol-jab-needs-a-rethink

'Inclisiran is a long-acting injection which only needs to be administered twice-yearly by your GP or nurse in a primary care setting and may even be prescribed in combination with other cholesterol-lowering agents such as statins.

'The drug is a chemically synthesised small-interfering RNA (siRNA) molecule which silences the gene (RNA) that makes a protein enzyme called PCSK-9. It results in an increased number of LDL receptors on cells which mop up LDL-cholesterol (LDL-C) from the circulation and in turn, leads to lower blood cholesterol levels.'

What could possibly go wrong?